Edge­wood's $20M Se­ries A; Nanoscope to pur­sue FDA ap­proval for eye gene ther­a­py lat­er this year

Plus, news about blue­bird bio, Q32 Bio and Aque­s­tive Ther­a­peu­tics:

Edge­wood On­col­o­gy’s $20M Se­ries A: The Brook­line, MA-based biotech plans to use the mon­ey to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER